102 related articles for article (PubMed ID: 20459297)
1. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.
Gao Y; Liu D; Wang H; Zhu J; Chen C
Xenobiotica; 2010 Jul; 40(7):467-75. PubMed ID: 20459297
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
Hanioka N; Matsumoto K; Saito Y; Narimatsu S
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
[TBL] [Abstract][Full Text] [Related]
3. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
[TBL] [Abstract][Full Text] [Related]
4. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
[TBL] [Abstract][Full Text] [Related]
5. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
Hichiya H; Tanaka-Kagawa T; Soyama A; Jinno H; Koyano S; Katori N; Matsushima E; Uchiyama S; Tokunaga H; Kimura H; Minami N; Katoh M; Sugai K; Goto Y; Tamura T; Yamamoto N; Ohe Y; Kunitoh H; Nokihara H; Yoshida T; Minami H; Saijo N; Ando M; Ozawa S; Saito Y; Sawada J
Drug Metab Dispos; 2005 May; 33(5):630-6. PubMed ID: 15716363
[TBL] [Abstract][Full Text] [Related]
7. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism.
Soyama A; Saito Y; Hanioka N; Murayama N; Nakajima O; Katori N; Ishida S; Sai K; Ozawa S; Sawada JI
Biol Pharm Bull; 2001 Dec; 24(12):1427-30. PubMed ID: 11767116
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8.
Jiang H; Zhong F; Sun L; Feng W; Huang ZX; Tan X
Amino Acids; 2011 Apr; 40(4):1195-204. PubMed ID: 20848147
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
[TBL] [Abstract][Full Text] [Related]
10. Examination of 209 drugs for inhibition of cytochrome P450 2C8.
Walsky RL; Gaman EA; Obach RS
J Clin Pharmacol; 2005 Jan; 45(1):68-78. PubMed ID: 15601807
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of human cytochrome P4502C8 by montelukast.
Walsky RL; Obach RS; Gaman EA; Gleeson JP; Proctor WR
Drug Metab Dispos; 2005 Mar; 33(3):413-8. PubMed ID: 15608135
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
13. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2008 Jan; 36(1):73-80. PubMed ID: 17913794
[TBL] [Abstract][Full Text] [Related]
14. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.
Bahadur N; Leathart JB; Mutch E; Steimel-Crespi D; Dunn SA; Gilissen R; Houdt JV; Hendrickx J; Mannens G; Bohets H; Williams FM; Armstrong M; Crespi CL; Daly AK
Biochem Pharmacol; 2002 Dec; 64(11):1579-89. PubMed ID: 12429347
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.
Kirchheiner J; Thomas S; Bauer S; Tomalik-Scharte D; Hering U; Doroshyenko O; Jetter A; Stehle S; Tsahuridu M; Meineke I; Brockmöller J; Fuhr U
Clin Pharmacol Ther; 2006 Dec; 80(6):657-67. PubMed ID: 17178266
[TBL] [Abstract][Full Text] [Related]
16. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.
Wang H; Kim RA; Sun D; Gao Y; Wang H; Zhu J; Chen C
Xenobiotica; 2011 Sep; 41(9):826-35. PubMed ID: 21692664
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.
Crespi CL; Chang TK; Waxman DJ
Methods Mol Biol; 2006; 320():103-7. PubMed ID: 16719379
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.
Yu L; Shi D; Ma L; Zhou Q; Zeng S
Biopharm Drug Dispos; 2013 Jul; 34(5):278-87. PubMed ID: 23536207
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza M; Pedersen RS; Nielsen F; Skougaard K; Wihl J; Keldsen N; Damkier P; Friberg LE; Peterson C; Vach W; Karlsson MO; Brosen K
Pharmacogenomics J; 2011 Apr; 11(2):113-20. PubMed ID: 20368717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
